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ABSTRACT OF THE THESIS
Effect of Monounsaturated Fat Rich Almonds on Hemostatic and Inflammatory Factors
in Healthy Adults
by
Kristianne M. Connell
Master of Science, Graduate Program in Nutrition Science
Loma Linda University, December 2001
Dr. Sujatha Rajaram, Chairperson

Background: The frequent consumption of nuts is inversely associated with the incidence
of cardiovascular disease. Nuts are known to decrease the risk of cardiovascular disease
by reducing serum total and low-density lipoprotein (LDL) cholesterol. Markers of
inflammation including C-reactive protein, E-selectin and interleukin-6 have been
proposed to be newer risk factors for cardiovascular disease. However, the influence of
nuts such as almonds on markers of inflammation and hemostasis that influence
cardiovascular disease risk is not currently known.
Objective: The objective of this study was to determine the effect of almond
consumption on markers of inflammation and hemostatic factors in healthy adults.
Design: This was a randomized, crossover, controlled feeding study. After a 2-week
run-in period on a typical American diet (34% energy from fat), subjects were
randomized to the Step I diet, low almond diet and high almond diet (0%, 10% or 20%
isoenergetic replacement of Step I diet with almonds respectively), for four weeks each.
Serum E-selectin, IL-6, CRP, fibrinogen, tPA ag and lipoprotein(a) were analyzed at the
end of each dietary period.

vm

Results: E-selectin was significantly lower on the almond diets and decreased as the
percentage of energy from almonds increased (P-trend <0.0001). CRP was statistically
significantly lower on the low (P=0.04) and high (P=0.03) almond diets in comparison to
the Step I diet. tPA was significantly lower on the Step I (P=0.01) and high almond
(P=0.004) diets compared with the low almond diet. Fibrinogen, IL-6 and lipoprotein(a)
were not significantly different between the three diets.
Conclusions: Consumption of almonds was able to lower levels of inflammatory
markers, E-selectin and CRP, which may be an indication of reduction in the
inflammatory process and thus impact CVD. However, other hemostatic and
inflammatory factors studied did not appear to be significantly influenced by the diets
enriched with almonds.
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CHAPTER ONE
I. INTRODUCTION
A. Statement of the Problem
Cardiovascular disease involves a complex and multifaceted progression that
impacts a large percentage of the population. Risk factors for cardiovascular disease are
many and often interrelated. It is well accepted that diet can play a role in cardiovascular
disease and lipid components in particular have been extensively researched. The
Mediterranean style of diet that consists of high monounsaturated fatty acid (MUFA)
intake is associated with lowered incidence of cardiovascular disease (Perez-Jimenez et al
1999, Carluccio et al 1999). It is known that monounsaturated fat decreases the risk of
cardiovascular disease by its beneficial effects on low-density lipoprotein (LDL) and
high-density lipoprotein (HDL) cholesterol (Kris-Etherton 1999). However, these effects
have not been able to completely account for the decreased cardiovascular disease risk in
countries consuming high MUFA diets (Perez-Jimenez et al 1999). In fact, it has
recently been shown that conventional risk factors for cardiovascular disease can only
explain less than half of the occurrence of cardiovascular events (Kullo et al 2000).
Some of the newer factors that have been shown to be possible factors involved in
cardiovascular disease include homocysteine, elevated fibrinogen, impaired fibrinolysis,
platelet reactivity, hypercoagulability, elevated lipoprotein(a), small dense low-density
lipoproteins, infectious agents and markers of inflammation (Kullo et al 2000). Increased
levels of fibrinogen, plasminogen activator inhibitor-1 (PAI-1), tissue plasminogen
activator (tPA) and factor VII have also been shown to be predictive of the incidence of
myocardial infarction in healthy middle aged adults (Anand et al 2000).
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Hemostasis is a complex and dynamic balance of coagulation and fibrinolysis. It
involves many activators and inhibitors that work together to keep the system functioning
properly. Coagulation and fibrinolytic factors can have an impact on cardiovascular
disease clinical endpoints and a model that describes their relationship has been proposed
(Figure 1) (Pearson et al 1997). Clinical endpoints that can be impacted include
myocardial infarction, unstable angina, atherothrombotic stroke and peripheral occlusive
disease.

It has been proposed that MUFA can have a beneficial influence on some of

Coagulation factors (+)
(TF-FVII, fibrinogen) \jThrombotic

Thrombotic
Fibrinolytic factors f-)^ Predisposition—> Occlusion
(tPA, plasminogen)
!
Atherogenic
Atherosclerosis—> Plaque Fissuring
Risk Factors

■>

"Myocardial Infarction
Unstable Angina
Atherothrombotic Stroke
Peripheral Occlusive Disease

Figure 1. Proposed model for the relationship between hemostasis factors and clinical
endpoints (Modified from Pearson et al 1997).

these factors and therefore on the hemostatic balance. Therefore several of the newer
factors associated with cardiovascular disease that are involved in hemostasis have been
investigated for their relationship with dietary fat and specifically with MUFA (Vorster et
al 1997, Kullo et al 2000). If it can be shown that MUFA has a beneficial impact on
hemostatic factors it will help to explain the additional reduction in cardiovascular
disease risk that has not been accounted for by more traditional risk factors such as blood
lipids and lipoproteins.
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B. Purpose of the Study
1. Objectives
The primary objective of this study is to understand the effect of almonds, which
are rich in monounsaturated fat, on inflammation and the hemostatic balance with the
implications for cardiovascular disease risk.
2. Specific aims/hypotheses
The specific aims of this study are:
a. To examine the effect of almonds on hemostatic factors.
Hypothesis: Almond diet will reduce the level of the hemostatic factors fibrinogen and
tissue plasminogen activator antigen.
b. To examine the effect of almonds on inflammatory factors.
Hypothesis: Almond diet will reduce inflammatory function as shown by lower levels
of markers of inflammation, namely E-selectin, C-reactive protein and interleukin-6.
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CHAPTER TWO
II. REVIEW OF THE LITERATURE
A. Hemostatic factors
Hemostasis is an intricate and beautifully designed system that balances the
process of coagulation and fibrinolysis through multiple pathways of activation,
inhibition and feedback mechanisms (Figure 2). It involves a complex and dynamic
process that must be able to act immediately to arrest bleeding. Yet it must also be able
to keep its effects from spreading beyond the local site of injury and avoid becoming
excessive which could lead to thrombosis formation. The process involves the vascular
endothelium, platelets, coagulation enzymes, fibrinolytic enzymes and the dynamics of
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Figure 2. Hemostatic balance involving the formation and dissolution of fibrin networks.
FX (factor X), FV (factor V), FXa (factor Xa), FVa (factor Va), tPA (tissue plasminogen
activator), uPA (urokinase plasminogen activator) (Vorster et al 1997).
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blood flow. It begins with an initial stimulus that sets off a cascade of reactions including
activation, adhesion and aggregation of platelets, coagulation activation, formation of a
platelet plug, stabilization and repair through the activation of the fibrinolytic enzyme
system (Figure 3).
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Figure 3. Platelet plug formation. Adenosine diphosphate, ADP; Thromboxane A2,
TXA2 (Harmening 1992).

The initial stimulus usually involves some type of injury to a vessel wall leading
to the exposure of the subendothelium to vascular contents. Normally vessels and their
endothelial lining provide an antithrombotic environment due to negatively charged
surfaces on platelets and the vascular endothelium, heparin sulfate, thrombomodulin,
prostacyclin, endothelial derived relaxing factor (EDRF) and plasminogen activators
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(Sherry 1992, Mann 1997). The negatively charged membranes repel one another and
heparin sulfate present in the endothelial glycocalyx weakly stimulates the primary
inhibitor of coagulation, antithrombin III (Sherry 1992, Harmening 1992). The
endothelium also contains thrombomodulin, which forms a complex with thrombin that
inhibits the ability of thrombin to stimulate clotting and also stimulates thrombin’s ability
to activate protein C, a specific and potent anticoagulant that is able to degrade factors Va
and Villa (Harmening 1992, Sherry 1992).

Prostacyclin (PGI2) and EDRF reduce the

amount of platelet aggregation and any fibrin that is able to form is degraded through
activation of plasminogen by plasminogen activators (Sherry 1992). All of these
components together make it difficult for a thrombus to form without some type of injury
to the vessel wall.
However, when the subendothelium is exposed to vascular contents the
surrounding environment changes to one that is more prone to thrombosis. Collagen
exposed in the subendothelium is able to bind platelets thus facilitating their activation.
The dense tubular system (DTS) within platelets is capable of synthesizing
prostaglandins and stores calcium which when released results in platelet contraction
(Harmening 1992). Platelets thus undergo internal activation leading to a shape change
and exposure of glycoproteins lb and Hb/IIIa on their surface. Glycoprotein lb forms a
complex with von Willebrand factor (vWf), which serves as a bridge linking collagen to
the platelets thus facilitating the adhesion of platelets to the exposed subendothelium and
the formation of a monolayer of platelets (Sherry 1992). The vWf is thus required for
platelet attachment to the endothelium and acts as a regulatory protein involved in
coagulation (George 1998). Megakaryocytes and endothelial cells produce vWf and it
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can be stimulated to bind by collagen, thrombin and adenosine diphosphate (ADP)
(Harmening 1992, Ogston 1983). Platelets then begin to aggregate to the site of injury
under the stimulus of thrombin, epinephrine, platelet activating factor (PAF), ADP or
thromboxane A2 (TXA2) (Sherry 1992). The glycoprotein complex Ilb/IIIa facilitates
the binding of platelets to fibrinogen in the presence of calcium thus linking the platelets
together and mediating the process of aggregation (Sherry 1992, Harmening 1992).
Activated platelets also release the contents of their granules, which produce a
second wave of aggregation. This release can be stimulated by TXA2, ADP and
epinephrine (Harmening 1992). Platelets have three types of granules including dense
granules, alpha granules and lysosomes. Dense granules contain ADP, adenosine
triphosphate (ATP), serotonin, epinephrine, norepinephrine, pyrophospate, calcium and
magnesium ions (Harmening 1992). Alpha granules contain fibrinogen, factor V, factor
VIII, vWf, plasminogen, albumin, PAI-1, a2-antiplasmin, platelet factor IV,
thromboglobulin, platelet derived growth factor (PDGF), fibronectin, thrombospondin
and permeability, bactericidal and chemotactic factors (Sherry 1992, Harmening 1992,
George 1998). Acid hydrolases are contained within the lysosomes and may serve to aid
in the cleanup of cellular debris after hemostasis (Sherry 1992, George 1998).
The aggregation of platelets is due to the release of ADP, serotonin and
arachidonic acid leading to the formation of TXA2 (Sherry 1992). TXA2 is a potent
platelet aggregator and is formed when ADP activates platelet membrane phospholipase
to produce arachidonic acid (Harmening 1992). Thrombospondin and fibronectin, which
are released from the alpha granules, help to hold the aggregation of platelets together by
forming a glue-like matrix until coagulation stabilizes the mass (Sherry 1992). The
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presence of ADP or epinephrine also leads to the exposure of fibrinogen receptors on
platelet membranes thus facilitating the binding of fibrinogen, which is also essential for
aggregation (Ogston 1983).
The platelet mass must then be stabilized through the process of coagulation.
Platelets have specific binding sites for fibrinogen and provide a catalytic surface for
coagulation reactions which helps to facilitate the formation of fibrin and the stabilization
of the platelet mass (Sherry 1992).
1. Coagulation
While platelets are adhering and aggregating to the site of vessel injury the
coagulation system is also getting underway. Two pathways have been described for the
coagulation system that leads to the formation of fibrin and stabilization of the platelet
mass. In both pathways a series of reactions are involved in which each product
produced acts as the enzyme for the next reaction thus resulting in amplification of the
system (Ogston 1983, Harmening 1992). The intrinsic pathway is initiated through
contact with a surface and utilizes the inactive clotting factors found normally in
circulation, while the more rapid extrinsic pathway is initiated by the release of tissue
factor (TF) after tissue damage (Ogston 1983, Harmening 1992, Sherry 1992). Although
they go about it differently, both the intrinsic and extrinsic pathways lead to the
activation of factor X.
In the intrinsic pathway (Figure 4) contact activation leads to activation of factor
XII to Xlla. Surface bound factor Xlla can then activate factor XI to factor XIa, which in
the presence of calcium ions can activate factor IX (Christmas factor) to IXa. Kallikrein
or high molecular weight kininogen (HMWK) is required for activation of factor XII to
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Xlla and factor XI to XIa and serves to amplify these reactions (Harmening 1992).
Factor IXa along with factor VIII, phospholipids and calcium ions can then activate
factor X (Stuart factor; Prower factor) (Ogston 1983, Harmening 1992).
Surface Contact
■> Factor Xlla

Factor XII

■>Kallikrein + HMWKa

Prekallikrein + HMWK
Surface

-> Factor Xlla

Factor XII
HMWKa

■> Factor XIa

Factor XI

Ca++
-> Factor IXa

Factor IX
Factor VIII, Ca++, PL

■> Factor X

Factor X
Factor V, Ca++, PL
Prothrombin

■> Thrombin

Fibrinogen

■> Fibrin

Factor Xllla
->Crosslinked Fibrin

Fibrin

Figure 4. Intrinsic coagulation pathway. HMWK, high molecular weight kininogen
(Adapted from Sherry 1992).

On the other hand the extrinsic pathway (Figure 5) begins with the release of TF
and the activation of factor VII. Factor VII is a proenzyme of coagulation produced in
the liver that can be converted to activated factor Vila by tissue factor and calcium, or
previously activated factor VII (Harmening 1992, George 1998). Factor Vila then forms
a complex with TF and in the presence of calcium can activate factor X to factor Xa and
factor IX to factor IXa (Ogston 1983, George 1998).
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Tissue Factor, Factor VII, Vila
Factor X

■> Factor Xa
Factor V, Ca++, PL

Prothrombin

■> Thrombin

Fibrinogen

Figure 5. Extrinsic pathway of coagulation (Adapted from Sherry 1992).

The activation of prothrombin to thrombin by factor Xa is facilitated by factor Va
which aids in the formation of a complex made up of phospholipids, factor Xa,
prothrombin and calcium ions (Ogston 1983, Harmening 1992). Platelets also serve to
localize the production of thrombin to the site of vessel injury by providing the
phospholipids required for activation of prothrombin (Ogston 1983). Thrombin is then
able to catalyze the conversion of fibrinogen to fibrin. Fibrinogen is the structural protein
of coagulation, which gels following thrombin cleavage and is capable of supporting
platelet aggregation (George 1998). Factor XIII is also activated by thrombin along with
calcium ions and is adsorbed to fibrin where it aids in the formation of covalent bonds
linking fibrin monomers thus serving to stabilize fibrin polymerization (Ogston 1983,
Harmening 1992). Thrombin therefore acts to amplify coagulation by activating factor
XIII, stimulating factor V and VIII, and platelet aggregation (Harmening 1992).
Although these two pathways have been traditionally used to describe the
coagulation system, they are unable to completely account for the reactions involved in
the coagulation system since it now appears that there is more overlap and interaction
between the two pathways (Harmening 1992). For example Factor Vila has been shown
to activate factor IX and that factor VII can be activated by factors IXa, Xa, and Xlla or
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thrombin (Harmening 1992). Factor Xa can also activate factor IX but at only 20% the
rate by which factor XIa activates it (Ogston 1983).
This process that results in the formation of a platelet plug must also be able to
overcome inhibition by several factors including tissue factor pathway inhibitor (TPFI),
antithrombin III, activated protein C (APC) and protein S. Tissue factor pathway
inhibitor functions as a regulatory protein of coagulation by inhibiting tissue factor
activated coagulation through the disruption of the factor VIIa-TF complex in the
presence of factor Xa and calcium (George 1998, Perez-Jimenez et al 1999).
Antithrombin III (also termed heparin cofactor or factor Xa inhibitor) is the major
inhibitor of the coagulation system and functions to inhibit thrombin and factors IXa, Xa,
XIa, and Xlla (Harmening 1992, Ogston 1983, Sherry 1992). Protein S is a cofactor for
protein C, a vitamin-K dependent proenzyme that when activated is capable of degrading
factors Va and Villa and competitively inhibiting factor Xa (Sherry 1992, Harmening
1992). Activated protein C also stimulates endothelial cells to release tissue plasminogen
activator (tPA) thus enhancing fibrinolysis (Harmening 1992). Fibrin/fibrinogen
degradation products (FDPs) have the ability to inhibit further coagulation by competing
with fibrinogen for thrombin (fragment X) and forming a nonclottable complex with
fibrin (fragment Y) thus hindering its polymerization (Harmening 1992). Plasmin also
acts to inhibit both platelets and coagulation by hindering platelets from aggregating and
by inactivating factors Va and Villa (Sherry 1992).
2. Fibrinolysis
On the other side of the hemostatic balance is the process of fibrinolysis, which is
essential in the regulation and localization of hemostasis. This process is activated along
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with activation of the coagulation system and leads to the gradual progressive
degradation of fibrin into soluble fragments that can be removed by the
reticuloendothelial system (RES) (Harmening 1992).
The major proteins involved in fibrinolysis are plasminogen and its activated
component plasmin. Plasminogen has lysine binding sites that are able to bind to fibrin
after it has been formed resulting in fibrin-bound plasminogen (Sherry 1992). The
activation of plasminogen depends on the presence of plasminogen activators, which can
come from either the intrinsic or extrinsic systems.
In the intrinsic system kallikrein is responsible for the conversion of plasminogen
to plasmin and is formed from prekallikren (Fletcher factor) by activated factor XII along
with HMWK (Sherry 1992). Kallikrein can also act on kininogens to produce kallidin or
bradykinin which can lead to increased vascular permeability, smooth muscle
contraction, dilation of blood vessels, inflammation and release of prostaglandins
(Harmening 1992). This system may be of importance in dissolving fibrin when there is
extensive vascular injury and inflammation but it is not the main pathway by which
plasmin is activated (Sherry 1992).
On the other hand, the extrinsic system appears to be the main regulator of
fibrinolysis. In this system plasminogen activators derived from tissue cells are found
normally in the circulation and can bind to the fibrin-plasminogen complex forming a
tertiary complex (Figure 6) (Sherry 1992). This complex is also important since
plasminogen activators require a surface to which plasminogen is bound in order to be
effective in their activation of plasminogen (Sherry 1992). Tissue plasminogen activator
is produced by endothelial cells and functions as an activator of the fibrinolytic system by
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stimulating the conversion of plasminogen to plasmin (Kullo 2000, George 1998).
Another plasminogen activator, prourokinase, is activated by plasmin or trypsin to
urokinase, which can then act on plasminogen (Ogston 1983).

Endothelial
Cell

Plasma

Fibrin
Clot

Fibrin Degradation Products
Figure 6. The process of fibrinolysis involving the dissolution of a fibrin network.
Endothelial cells secrete tissue plasminogen activator (tPA), which in plasma forms an
inactive complex with plasminogen activator inhibitor-1 (PAI-1). When tPA is bound to
fibrin plasminogen (Pg) is able to bind and becomes converted to plasmin (P), which
actively digests fibrin. a2-Antiplasmin (PI) neutralizes any free plasmin released.
Broken arrows represent inhibition of fibrinolysis (George 1998).

The formation of a tertiary complex and the need for a membrane surface also
helps in keeping plasminogen in the plasma from being activated and therefore keeping
the fibrinolytic system localized to the site of vessel injury (Sherry 1992). Thrombin,
through its activation of protein C, helps to keep the system localized since it is a major
activator in the release of plasminogen activators from the endothelium and it is produced
13

only at the site of vessel injury (Harmening 1992, Sherry 1992). Activated protein C
inhibits plasminogen activator inhibitor-1 and along with its cofactor protein S,
inactivates factor Va and factor Villa thus resulting in negative feedback regulation of
coagulation (Harmening 1992). Limiting activation of plasminogen to fibrin aids in
allowing fibrin to be the only immediate substrate on which plasmin can act since it is a
nonspecific, proteolytic enzyme that can also act on several other substrates such as
fibrinogen, factor V, factor VIII, fibronectin and thrombospondin (Sherry 1992).
When fibrin is formed in the presence of plasminogen activators fibrinolysis is
more rapid since plasminogen activators can become incorporated throughout the fibrin
matrix resulting in activation of fibrin-bound plasminogen in the matrix all at once
(Sherry 1992). Fibrin-bound plasmin is capable of degrading fibrin into soluble fibrin
fragments and thus destroying and initiating the repair of the platelet mass and
endothelial vessel injury.
The platelet membrane can bind plasminogen and in the presence of plasminogen
activators convert it to plasmin. Plasmin can then degrade the glycoproteins that are
connecting the platelets to one another (Hb/IIIa) and to the subendothelium (lb) resulting
in disruption of the platelet adhesion and aggregation (Sherry 1992). The platelet
aggregation is disrupted through the binding of plasminogen to thrombospondin leading
to its degradation as well as the degradation of fibronectin (Sherry 1992).
However, there are also inhibitors of the fibrinolytic system. The primary
inhibitor of plasmin is a2-antiplasmin, which is able to form an inactive one to one
complex with plasmin (Ogston 1983, Sherry 1992). Other, more weakly acting inhibitors
of plasmin include a2-macroglobulin and to a more limited extent ai-antitrypsin and
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antithrombin III (Sherry 1992). Inhibitors can readily act on plasmin that is free,
however, when it is bound to fibrin it is protected from inhibitors since fibrin and plasmin
inhibitors bind to the same site on the plasmin molecule (Sherry 1992). Therefore the
activity of plasmin is limited to the area of fibrin deposition.
There are also inhibitors of plasminogen activators such as plasminogen activator
inhibitor-1 (PAI-1). Plasminogen activator inhibitor-1 is a serine protease inhibitor
produced by the endothelium that has high affinity for tPA and therefore can inhibit the
fibrinolytic system (George 1998, Pearson et al 1997). PAI-1 and tPA form a complex
together and therefore tPA is inversely related to PAI-1 activity (Pearson et al 1997). Obantiplasmin and ai-antitrypsin are slow acting inhibitors of plasminogen activators
(Sherry 1992). Inhibitors are important in limiting the action of fibrinolysis to the site of
injury and in preventing fibrinolysis from taking place too soon, which could lead to
rebleeding (Sherry 1992).
Hemostasis is an amazing system capable of keeping blood in a fluid state
throughout the vasculature and yet also able to quickly respond to the needs of vessel
injury and repair without leading to the formation of damaging thrombi and emboli.
B. Inflammation
The process of inflammation is an important aspect involved in the progression of
atherosclerosis and cardiovascular disease events. Atherosclerosis may involve
subclinical thrombosis and inflammation that can result in activation of the hemostatic
process (Pearson et al 1997).
When there is injury to the vascular endothelium the inflammatory process is
stimulated and involves fluid, protein and leukocyte migration into tissues (Sigal and Ron
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1994). Chemotactic factors are produced in large amounts at sites of tissue injury and are
involved in the processes of margination, adhesion and chemotaxis (Fantone and Ward
1994). Margination results in leukocytes being pushed toward the vascular wall, which
facilitates their adhesion to endothelial cells and the basement membrane (Fantone and
Ward 1994, Sigal and Ron 1994).
Tissue injury leads to the exposure of several types of adhesion molecules, which
aid in recruiting leukocytes and platelets to the site of vessel injury and inflammation
(Fantone and Ward 1994). Lectin-cell adhesion molecules such as E-selectin (also called
endothelial leukocyte adhesion molecule-1, ELAM-1) and leukocyte adhesion molecule1 (LAM-1) help to localize leukocytes to the site of injury (Fantone and Ward 1994, Sigal
and Ron 1994). E-selectin is produced by endothelial cells and is stimulated by cytokines
such as tumor necrosis factor-a (TNF-a) and interleukin-1 (IL-1) (Perez-Jimenez et al
1999, Fantone and Ward 1994). Cytokines can stimulate the exposure of intercellular
adhesion molecule-1 (ICAM-1) and intercellular adhesion molecule-2 (ICAM-2), which
aid in localization and adhesion of inflammatory cells (Fantone and Ward 1994).
Integrins including lymphocyte function-associated antigen (LFA-1), Mol and Leu-M5
aid in the recruitment and migration of leukocytes along with their phagocytic and
cytotoxic functions (Sigal and Ron 1994, Fantone and Ward 1994). Upregulation of
integrins is stimulated by several factors including TNF-a and PAF (Sigal and Ron
1994). Cytokines are involved in the recruitment of inflammatory cells to sites of vessel
injury through cell-to-cell communication and help to regulate the expression of adhesion
molecules (Fantone and Ward 1994). Interleukin-8 (IL-8) stimulates chemotaxis and
interleukin-6 (IL-6) promotes systemic inflammatory response (Fantone and Ward 1994).
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IL-6 is an inducible endothelial protein that is involved in the amplification of the
inflammatory response whose expression may be controlled by nuclear factor-kappaB
(NF-kB) system since genes for IL-6 as well as genes for TNF-a and adhesion molecules
have promoter-binding sites for NF-kB (De Caterina et al 2000, Hennig et al 2000). IL-6
can be produced at the site of inflammation where it can stimulate hepatocytes to
synthesize acute phase proteins such as C-reactive protein (CRP) and fibrinogen (Fantone
and Ward 1994). Fibrinogen therefore may be increased due to inflammation and result
in the aggravation of injury to vessel walls (Kullo et al 2000). Additional coagulation
factors may be increased by fibrinogen, including factor V, factor VIII and factor XIII
(Harmening 1992).
Research has shown CRP to be directly associated with IL-6 levels (Kullo et al
2000). Moderately elevated levels of CRP, is an indicator of systemic inflammation and
has been linked with increased risk of myocardial infarction and ischemic stroke as well
as increased risk of CVD in several studies including the Physicians’ Health Study and
the Women’s Health Study (Cleland et al 2000, Kullo et al 2000). CRP may act to
increase the expression of tissue factor or it may activate cytokines that result in
leukocyte adhesion (Pepys and Berger 2001, Kullo et al 2000). CRP may be able to
initiate the activation of the complement system through its ability to bind LDL in
atherosclerotic plaques, which along with its other functions is important in mediating
inflammation (Sigal and Ron 1994, Pepys and Berger 2001). Activated complement is
able to mediate several aspects of inflammation including chemotaxis, vasodilation and
cytokine stimulated secretion of TNF-a and IL-1 (Sigal and Ron 1994).
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It is thought that inflammatory cells within plaques contribute to their weakening
that can lead to rupture and formation of a thrombus (Alexander 1994). Acute
exacerbations or activation of low-grade chronic inflammation leads to injury of vessel
tissue or disruption of an atherosclerotic plaque resulting in exposure of prothrombotic
factors within the plaque and activation of the hemostatic process which can potentially
precipitate CVD events (Alexander 1994, Pearson et al 1997, National Heart Foundation
of Australia 1999).
C. Diet and hemostatic and inflammatory factors
Because diet is a readily modifiable risk factor for CVD many studies have
investigated the effects of diet on hemostatic and inflammatory factors. Some animal
studies have shown that saturated fat (SFA) is associated with increased clotting and
thrombosis while eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) may be
protective against thrombosis (FitzGerald and Barry 1997, Hoak 1997). However, this
paper will focus on results from human studies. Some of the dietary components that
have been shown to influence hemostatic and inflammatory factors include fiber, vitamin
E, garlic, alcohol and fat.
1. Fiber
Fiber intake has been linked with several hemostasis factors including fibrinogen,
factor VII, tPA and PAI-1. Soluble fiber intake is associated with lower levels of
fibrinogen (Vorster et al 1997). Oat bran supplements may lower factor Vile levels
although only in high amounts (Marckmann et al 1998). It appears that factor Vile levels
along with factor X and factor VIII are lower after diets high in fiber (Mennen et al 1997,
Vorster et al 1997). In the Rotterdam Study (Table 1) fiber was inversely correlated with
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factor Vile in men and women (Mennen et al 1997). It has been proposed that switching
from a high-fat Western diet to a low-fat diet high in fiber can lower factor Vile levels by
5-25% (Marckmann et al 1998).
Table 1. Regression coefficients and 95% confidence intervals for dietary factors and
factor VII activity in men and women i
Women
Men
(|3; 95% Cl)
(P; 95% Cl)
Fiber (g)
-0.36 (-0.63, -0.09)
-0.31 (-0.57,-0.06)
0.10(0.005,0.20)
0.005 (-0.08, 0.09)
Total fat (%/g)
0.18(0.001,0.36)
Saturated fat (%/g)
0.11 (-0.06, 0.27)
0.04 (-0.16, 0.24)
-0.15 (-0.33,0.03)
Polyunsaturated fat (%/g)
Monounsaturated fat (%/g)
0.17 (-0.05, 0.39)
0.03 (-0.15,0.20)
Modified from Mennen et al 1997

An intake of a low-fat, high fiber diet for 8 months was shown to increase tPA
levels, however, another study showed that a high complex CHO, low-fat diet for 3
weeks lowered tPA levels (Vorster et al 1997). Fiber has been shown to lower PAI-1
levels when subjects consumed a high complex CHO, low-fat diet for three weeks
(Vorster et al 1997).
2. Vitamin E
Vitamin E may be able to influence levels of fibrinogen and monocyte adhesion.
Oleic and palmitic acids both with and without vitamin E were shown to lower fibrinogen
levels, however fish oil was only able to lower fibrinogen levels after vitamin E was
added (Vorster et al 1997). Addition of vitamin E to different 18 carbon fatty acids
cultured with endothelial cells resulted in reduced activation of NF-kB in stearic and
linoleic acids, which could lead to less monocyte adhesion (Hennig et al 2000).
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3. Garlic
Garlic may play a role in platelet aggregation involved in hemostasis. In one
study 18 mg of garlic oil or 10 g of fresh garlic cloves were shown to decrease platelet
aggregation by 16.4% and 58% respectively (Lampe 1999).
4. Alcohol
Epidemiological data has shown alcohol intake to have an inverse or U-shaped
relationship with fibrinogen (Vorster et al 1997). Alcohol is positively associated with
increased levels of tPA in men and women while it is only associated with increased PAI1 levels in men (Vorster et al 1997).
5. Fat
Total fat intake has been positively associated with factor VII levels in women,
tPA and PAI-1 levels (Mennen et al 1997, Vorster et al 1997). Lowering fat intake has
been shown to lower PAI-1 levels but the reduction may need to be more than 8% in
order to elicit benefits in hemostatic factors (Vorster et al 1997).
Different types of fat appear to have an impact on several factors involved in
coagulation, fibrinolysis and inflammation. Some of the factors that appear to be
influenced include platelet aggregation, fibrinogen, factor VII, adhesion molecules, tissue
plasminogen activator, plasminogen activator inhibitor-1 and interleukin-6.
a. Platelet aggregation
While SEA intake may lead to increased platelet aggregation (National Heart
Foundation of Australia 1999), intake of n-3 PUFAs and diets with a high ratio of
PUFA/SFA may beneficially influence platelet aggregation (Kullo et al 2000). However,
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in a study of 17 vegetarian men differing in the ratio of n-3:n-6 PUFAs no significant
difference in platelet aggregation was observed (Li et al 1999).
b. Fibrinogen
The effects of linoleic acid, a-linolenic acid, EPA and DHA on fibrinogen levels
have been inconsistent (Knapp 1997, Miller 1998). Fibrinogen has been shown to be
inversely related to n-3 PUFA intake (Sanders et al 1997). A cross-over experimental
study comparing diets rich in SFA, n-3 PUFA and n-6 PUFA intake showed that
fibrinogen was about 10% higher in the n-6 PUFA diet than the n-3 PUFA or SFA diets
(Sanders et al 1997). However, another study did not show any significant difference in
fibrinogen levels from diets differing in the ratio of n-3:n-6 PUFAs (Li et al 1999).
c. Factor VII
Fatty acids play a role in determining the levels of factor Vile (Mennen et al
1997). In the Rotterdam Study (Table 1) it was seen that among women intake of SFA
and MUFA were positively associated with factor Vile (Mennen et al 1997). In men
SFA was positively associated with factor Vile while PUFA was inversely associated
(Mennen et al 1997).
Although there have been conflicting results in studies looking at n-3 PUFAs and
factor Vile most have shown no significant effect (Sanders et al 1997, Li et al 1999,
Miller 1998). A cross-over experimental study showed that factor Vile did not differ
between the n-6 and n-3 diets although it was higher during the n-3 PUFA diet in
comparison to the SFA diet and the n-6 PUFA diet (Sanders et al 1997). Another study
of diets with differing ratios of n-3:n-6 PUFAs did not show any significant difference in
factor VII (Li et al 1999).
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Postprandial factor Vile levels increase after a high-fat meal irrespective of the
type of fat in the meal (Marckmann et al 1998, Mennen et al 1997, National Heart
Foundation of Australia 1999). Additionally it appears that the background diet is more
important than the composition of the high-fat test meal. When the background diet is
rich in SFA, a high-fat PUFA rich meal results in increased factor VII levels but not
when the background diet is rich in PUFA (Miller 1998).
d. Adhesion molecules
vWf has been shown to be inversely related to n-3 PUFA intake (Sanders et al
1997). On the other hand a cross-over experimental study comparing diets rich in SFA,
n-3 PUFA and n-6 PUFA intake showed that vWf was lower during the SFA diet than the
other diets (Sanders et al 1997). DHA has been shown to be capable of inhibiting
cytokine inducible adhesion molecules including VCAM-1 (vascular cell adhesion
molecule-1), E-selectin and ICAM-1 (Carluccio et al 1999; De Caterina et al 2000).
e. Fibrinolytic factors
Diets differing in type of fatty acid do not appear to influence tPA levels (Sanders
et al 1997). However, both SFA and n-6 PUFA intake have been shown to be directly
correlated with PAI-1 levels even taking into account age and body mass index (BMI)
(Hansen et al 2000). There is some thought that n-3 PUFAs may be beneficial on
fibrinolytic activity however the effect of EPA and DHA on PAI-1 levels has been
inconsistent (Knapp 1997). A double-blind, placebo controlled study of diets
supplemented with either EPA, DHA or corn oil showed that PAI-1 was increased on all
diets and that they were not significantly different from one another (Hansen et al 2000).
Although EPA and DHA were not correlated with PAI-1 activity it was seen that there
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were positive correlations with PAI-1 and fat intake, especially SFA (Hansen et al 2000).
Another study showed no difference in PAI-1 levels among diets rich in SFA, n-3 PUFA
and n-6 PUFA (Sanders et al 1997).
An in vitro study has shown that PAI-1 transcription and secretion by endothelial
cells is increased in response to VLDL and unsaturated fatty acids (oleic, linoleic,
linolenic and EPA) (Nilsson et al 1998). This response appears to be mediated through
binding of a VLDL-inducible transcription factor to a VLDL response element in the
PAI-1 gene promoter region (Nilsson et al 1998).
f. Monocyte adhesion, IL-6
DHA and EPA have been implicated in protection from atherosclerosis by
influencing monocyte adhesion to endothelial cells potentially by inhibition of
transcription factor NF-kB, which is critical in the cytokine network regulation
(Carluccio et al 1999, Hennig et al 2000). In vitro studies have found that SFA and
PUFA cultured with endothelial cells can activate NF-kB, while MUFA had little effect
(Hennig et al 2000). Intake of n-6 PUFA was seen to have the greatest effect in
increasing endothelial permeability while MUFA and n-3 PUFA did not disrupt the
barrier function of the endothelium (Hennig et al 2000). Endothelial cells cultured with
n-6 PUFA greatly increased the production of IL-6 after exposure to TNF-a in
comparison to endothelial cells alone or cultured with SFA, MUFA or n-3 PUFA (Hennig
et al 2000). The amount of PUFA has been positively associated with monocyte
adhesion (Mata et al 1996). A diet rich in n-3 PUFA has been shown to have
significantly greater amounts of monocyte adhesion than the diets rich in SFA, MUFA or
n-6 PUFA (Mata et al 1996).
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It appears that DHA, but not EPA, is able to influence cytokine mediated
activation of the endothelium and thus may lower the susceptibility to inflammation
(National Heart Foundation of Australia 1999). DHA has been shown to be capable of
inhibiting cytokine inducible adhesion molecules, IL-6 and IL-8 (Carluccio et al 1999;
De Caterina et al 2000). Since SEA has been shown to be unable to influence endothelial
activation it appears that fatty acids must contain at least one double bond in order to
impact the activation of the endothelium (Carluccio et al 1999). The position and
configuration of these double bonds does not appear to make any difference, however,
increasing number of double bonds does seem to result in increased impact (Carluccio et
al 1999). It is therefore possible that fatty acids can function as regulators for a cells
response in the presence of cytokines (De Caterina et al 2000).
Diet appears to play an important role in hemostasis and inflammation related to
cardiovascular disease even though the results have often been controversial and
conflicting. It seems fairly clear that lowering intake of SEA by replacing it with either
MUFA or PUFA is beneficial in reducing the risk of cardiovascular disease and
improving hemostatic and inflammatory factors (Kris-Etherton 1999). There is some
indication that MUFA may have added benefits over PUFA due to its ability to reduce
FDL susceptibility to oxidation and potential benefit on coagulation, fibrinolysis and
inflammation (Kris-Etherton 1999). Since the focus of this paper is on MUFA the effects
of MUFA on hemostatic and inflammatory factors will be examined in more detail.
D. MUFA and Hemostasis
Table 2 summarizes the studies that have examined the effect of MUFA diets on
hemostatic and inflammatory factors. A randomized, cross-over study (Fopez-Segura et
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Table 2. Human studies examining the effect of MUFA on hemostatic and inflammatory
factors.
Reference

Subjects

Lopez22 healthy
Segura et men (23.4
al, 1996
±5.6yrs)
Temme et 32 men
al, 1999
and
women
(22-60
years)

Study design
Randomized
crossover

Six
weeks
each diet
(2-3
week
washout)
periods
4 weeks
each diet
(2 month
washout
period)
21 days
each diet
(3-12
week
washout
period)

18 men
(21-28 yrs)

Randomized
crossover

Larsen et
al, 1999

18 healthy
men (2028 yrs)

Double-blind
crossover

Roche et
al, 1998

23 healthy
men
Family
history of
MI (28.7 ±
6.6 yrs)
25 men,
normolipemic
(<30 yrs)

Randomized
single-blind
crossover

12
NIDDM
men and
women
(50.7 ±7.8
yrs)

Unblinded,
crossover

Vischeret
al, 1998

24 days
each diet

Randomized
crossover

Tholstrup
et al,
1999

PerezJimenez
et al,
1999

Length

Consecutive

8 weeks
each diet
(8-10
week
washout
period)
28 days
each diet

3 weeks
each diet
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Diet

Factors
Studied
• High-MUFA Fibrinogen
tPA
• Step I
PAI-1
Fibrinogen
• High lauric
Factor VII
acid
PAI-1
• High
palmitic
acid
. High oleic
acid
Fibrinogen
• High oleic
Factor VII
acid diet
tPA
• High
PAI-1
palmitic
acid diet
Factor VII
• HighPost
MUFA
prandial
(olive oil)
factor VII
diet
• High-PUFA
(sunflower
oil) diet
• HighMUFA
(rapeseed
oil) diet
Post• Highprandial
MUFA
factor VII
(olive oil)
diet
• High-SFA
diet
vWf
• Step I diet
PAI-1
• HighE-selectin
MUFA diet
• High-SFA
diet

• HighMUFA diet
• High-CHO
diet

vWf

Results
High-MUFA
vs. Step I:
j PAI-1
Oleic acid vs.
Palmitic acid:
st Factor VII,
i PAI-1
Oleic acid vs.
Laurie acid:
F Factor VII
High oleic
acid vs. high
palmitic acid:
No sign.
Difference
Olive oil vs.
sunflower oil:
F postprandial
factor VII

High-MUFA
vs. High-SFA\
F postprandial
factor VII

High-MUFA
vs. Step I:
i vWf,
F PAI-1
High-MUFA
vs. High-SFA:
F vWf,
F PAI-1
High-MUFA
vs. HighCHO:

F vWf

al 1996) of 22 men (mean age of 23.4 ± 5.6 years), compared a MUFA diet (38% energy
from fat, 10%SFA, 22%MUFA, 6%PUFA) to the National Cholesterol Education
Program Step I (Step I) diet (30% energy from fat, 10%SFA, 14%MUFA, 6%PUFA)
with two levels of cholesterol (115 mg vs. 290 mg/1000 kcal). All foods were prepared
and eaten on site during the four diet periods which lasted 24-days each and olive oil was
used as the source of fat for the MUFA diets. There was no significant difference in
levels of fibrinogen or tPA antigen however there were significant differences in PAI-1
antigen and PAI-1 activity levels.
Another randomized, cross-over study (Temme et al 1999) of 32 men and women
(ages 20 to 60 years) compared three experimental diets consisting of 41% of energy as
fat from lauric, palmitic or oleic acids consumed in the form of margarine. The subjects
were randomized into six groups that followed each of the three diets for six weeks in
different orders. There were 2-3 week washout periods between the experimental diets
during which subjects consumed their habitual diet. There was no significant difference
in fibrinogen levels. However, fibrinogen levels did tend to be higher in the lauric and
palmitic enriched diets than in the oleic acid diet. Levels of factor Vllam and PAI-1
activity were significantly lower after the oleic acid diet.
A modified butter high in oleic acid (diet M) has been compared to conventional
Danish butter that is high in palmitic acid (diet D). In this study (Tholstrup et al 1999),
eighteen men (ages 21 to 28 years) consumed two experimental diets for 4 weeks each in
random order with a 2-month washout period in between during which they consumed
their regular diet. Both experimental diets contained 40% energy from fat of which 30%
came from butter, which was served as spreads and used in bread, rolls and cakes. All
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foods were prepared in the research kitchen and lunches were served on weekdays while
all other meals were provided as take out packages. This study showed no significant
difference between the two diets on levels of fibrinogen, factor Vile, tPA or PAI-1
antigen. Factor Vile was lower postprandially following a high-fat meal of the modified
butter diet compared to the conventional butter diet (P<0.05), although only marginally.
Two studies have examined postprandial effects of diet on hemostatic factors,
particularly factor VII. In a double-blind, crossover study 18 healthy individuals (ages 20
to 28 years) were randomized into six groups and consumed each of the three
experimental diets for 21 days in different orders with 3 to 12 week washout periods in
between during which they consumed their habitual diets (Larsen et al 1999). The three
experimental diets were identical except for the source of oil, which made up 19% of
energy intake and consisted of either olive oil (35% energy from fat, 8%SFA,
17%MUFA, 2%PUFA), sunflower-oil (35% energy from fat, 7%SFA, 8%MUFA,
12%PUFA) or rapeseed-oil (35% energy from fat, 7%SFA, 15%MUFA, 6%PUFA). All
foods were provided for participants and lunches were eaten at a central location while
the rest of the meals were prepackaged and eaten at home. The olive oil diet resulted in
decreased levels of postprandial activated factor VII (Vila) compared to the sunflower oil
diet (P<0.01) and also tended to be lower on the olive oil diet in comparison to the
rapeseed-oil diet (P=0.09). However fasting levels of factor Vila and factor Vile were
not significantly different in the three diets.
In a similar randomized, single-blind crossover study, 23 healthy men with family
histories of myocardial infarction consumed background diets rich in olive oil or SFA.
The subjects consumed each diet for 8 weeks in random order with an 8-10 week
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washout period in between. In both diets approximately 40% of energy was supplied by
fat. Postpandial levels of factor VII were measured after consumption of 40 grams of
olive oil during each diet. When the background diet was rich in olive oil there were
lower postprandial factor Vila (P=0.04) and factor VII antigen (VIlag) levels (P=0.006)
than with a high SFA background diet (Roche et al 1998). Postprandial factor VIlag was
also elevated for a longer period following the SFA diet than the MUFA diet (P<0.05).
In a study (Perez-Jimenez et al 1999) of 25 normolipemic male students, subjects
consumed three diets for 28 days each in which all meals were eaten on site or provided
to be eaten at home. They first consumed a Step I diet (28% energy from fat, 10% SFA,
12% MUFA and 6% PUFA), followed by a high MUFA diet (38% energy from fat, 10%
SFA, 22% MUFA and 6% PUFA) and then a high SFA diet (38% energy form fat, 20%
SFA, 12% MUFA and 6% PUFA). The high-fat MUFA diet rich in olive oil was able to
significantly decrease vWf and PAI-1 levels. However, levels of E-selectin showed no
significant difference.
A crossover study (Vischer et al 1998) of 12 NIDDM subjects compared a high
MUFA diet (36% CHO, 50% fat with 30% from MUFA) with a high carbohydrate diet
(49% CHO, 32% fat with 11% MUFA). Each diet was followed for three weeks. The
results showed that there was a significant decrease in vWf and its propeptide on the
MUFA diet with a decrease of 21.8% after the MUFA diet (P<0.05) versus an increase of
6.8% after the CHO diet (P=0.09).
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1. Coagulation factors
a. Fibrinogen
Fibrinogen functions as the substrate for coagulation and increased concentrations
are linked with increased risk of cardiovascular disease. Several studies comparing
MUFA with other fatty acids have shown no significant difference in fibrinogen levels
(Lopez-Segura et al 1996, Temme et al 1999, Tholstrup et al 1999). However, there is
some indication that fibrinogen levels tend to be lower with an oleic acid diet (Temme et
al 1999). Although diet may be able to impact fibrinogen levels, current research has not
been able to demonstrate any effect of a diet rich in monounsaturated fat.
b. Factor VII
Epidemiologic data supports a link between diet and factor VII (Marckmann et al
1998). It also appears from experimental studies that factor VII may be impacted by the
type of fat ingested. One study has shown that factor Vllam levels are lowered by a diet
rich in MUFA (Temme et al 1999) while others have found no significant difference in
factor Vile or factor Vila levels (Tholstrup et al 1999, Larsen et al 1999).
A MUFA rich diet does appear to result in lower postprandial levels of factor
Vila, factor VIlag and factor Vile (Larsen et al 1999, Roche et al 1998, Tholstrup et al
1999). Postprandial factor VIlag was also elevated for a longer period following a SFA
diet than a MUFA diet (P<0.05) (Roche et al 1998).
Other studies that have examined the effects of fat composition on postprandial
factor VII levels by only controlling the composition of an acute high-fat test meal have
shown that, irrespective of fatty acid composition, a high-fat meal will increase factor
Vile (Marckmann et al 1998, Larsen et al 1997, Roche and Gibney 1997, Oakley et al
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1998). A few studies have shown a more rapid rise in factor VII activity postprandially
with high monounsaturated meals, which could be potentially more beneficial than a
prolonged elevation (Roche and Gibney 1997, Oakley et al 1998). These studies indicate
that factor VII is more influenced by the background diet than an acute high-fat test meal.
When the background diet is high in SFA, a high-fat test meal has shown increases in
postprandial factor Vile whether the test meal is rich in SFA, MUFA or PUFA (Miller
1998). It has been shown that factor Vila activity is inversely associated with the
proportion of oleic acid in nonesterified fatty acids (NEFAs) and the dietary intake of
oleic acid (Roche et al 1998). From these studies it does appear that MUFA can
beneficially influence factor VII levels and that postprandial factor VII levels may be
impacted more than fasting levels.
c. von Willebrand factor
As an adhesion molecule, vWf is essential in the formation of a platelet
monolayer at the site of vessel injury and thus aids in the initial phase leading to
coagulation. Several studies have shown that MUFA diets are able to significantly
decrease levels of vWf (Perez-Jimenez et al 1999, Vischer et al 1998, Knapp 1997).
From these studies it appears that a MUFA rich diet is able to beneficially impact levels
of vWf. Such a decrease could promote a more antithrombotic environment thus
lowering the risk of cardiovascular disease.
2. Fibrinolytic factors
a. Tissue plasminogen activator
As an important plasminogen activator, tPA, is critical in fibrinolysis. A few
studies have examined the effect of MUFA on tPA and have consistently shown no
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significant difference in tPA levels (Lopez-Segura et al 1996, Tholstrup et al 1999). The
type of fat (oleic acid, butter, or oleic acid with MCT oil) and amount of fat (95 grams or
18 grams) does not appear to influence postprandial tPA levels (Oakley et al 1998).
Therefore it appears that MUFA does not play a significant role in levels of tissue
plasminogen activator.
b. Plasminogen activator inhibitor-1
Although tPA levels do not currently appear to be influenced by high MUFA
diets, the inhibitor of tPA does seem to be significantly impacted by MUFA diets.
Theoretically elevated concentrations can lead to the inhibition of the fibrinolytic system
(Pearson et al 1997). Most studies that have examined the effect of MUFA on PAI-1
levels have found that a MUFA rich diet can significantly lower PAI-1 levels (LopezSegura et al 1996, Perez-Jimenez et al 1999, Temme et al 1999), however, one study
showed no significant difference (Tholstrup et al 1999). Although there are some
conflicting results, the majority of studies indicate that MUFA diets can influence
fibrinolysis by impacting levels of fibrinolytic inhibitors and therefore leading to a
decrease in risk of cardiovascular disease. One study in which patients who had
experienced a myocardial infarction were followed for three years and it was shown that
increased PAI-1 was able to independently predict occurrence of a second myocardial
infarction (Pearson et al 1997). These results are consistent with epidemiological studies
which have implicated elevated PAI-1, instead of lower tPA levels, as being the cause of
reduced fibrinolytic activity seen in atherothrombotic disease (Hansen et al 2000).
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E. MUFA and Inflammatory factors
Replacing SEA with MUFA instead of PUFA may be more beneficial in
preventing CVD. It has been seen that n-6 PUFA has the greatest ability to activate
endothelial cells thus contributing to the inflammatory response (Hennig et al 2000). On
the other hand oleic acid has not been shown to cause endothelial cell activation and may
protect against oxidative damage in endothelial cells (Hennig et al 2000). An in vitro
study of oleic acid cultured with endothelial cells showed that it was able to inhibit
leukocyte and monocyte adhesion molecules as a result of mRNA inhibition due to
inhibition of NF-kB stimulation (Carluccio et al 1999). Oleic acid appears to selectively
replace SFA in membranes, which would leave room for potentially additive effects of
oleic acid and n-3 PUFA in inhibiting endothelial activation (Carluccio et al 1999, De
Caterina et al 1999).
Monocyte adhesion to endothelial cells was studied in 42 healthy men and women
who consumed four consecutive diets differing in the type of fat content of SFA (35.5%
energy from fat; 17.3%SFA, 13.6%MUFA, 3.6%PUFA), MUFA (35.2% energy from fat;
9.2%SFA, 20.9%MUFA, 4%PUFA), n-6 PUFA (35.6% energy from fat; 9.5%SFA,
12%MUFA, 12.5%PUFA) and n-3 PUFA (35.1% energy from fat; 9.2%SFA,
11.8%MUFA, 12.7%PUFA) for five weeks each (Mata et al 1996). Human umbilical
vein endothelial cells were cultured with LDL isolated at the end of each diet period to
see the effect of diet on monocyte adhesion. The MUFA diet (6.6 ± 0.7%) had
significantly less adhesion than was seen in the SFA and n-3 PUFA diets (9.1 ± 2.0% and
13.2 ± 2.9%; P<0.05) and tended to be lower than in the n-6 PUFA (7.9 ± 1.2%) diet
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period. The amount of MUFA content in the LDL phospholipids was inversely
correlated with the amount of adhesion (r = -0.5138, P=0.0005).
1. E-selectin
The presence of one double bond present in monounsaturated fatty acids is
sufficient to inhibit expression of adhesion molecules including E-selectin, however,
higher concentrations may be necessary than with the more highly unsaturated fatty acids
(De Caterina et al 1999). When human adult saphenous vein endothelial cells (HSVEC)
were incubated with oleic acid, linoleic acid, arachidonic acid, eicosapentaenoic acid
(EPA) and docosahexaenoic acid (DHA) it was seen that DHA, and oleic acid to a lesser
degree, was able to inhibit expression of adhesion molecules (De Caterina and Libby
1996).
In particular, E-selectin was shown to be inhibited along with other adhesion
molecules in one in vitro experiment that cultured human umbilical vein endothelial cells
(HUVECs) with oleic acid (Carluccio et al 1999). It has been proposed that oleic acid
may have its influence on adhesion molecules through a common pathway of NF-kB and
its activation has been shown to decrease in cells treated with oleic acid (Carluccio et al
1999, De Caterina et al 1999).
One experimental study found that E-selectin levels were not significantly
different between the Step I, MUFA or SFA diets (Perez-Jimenez et al 1999). Although
MUFA has been shown to be able to inhibit E-selectin in vitro such an effect has not yet
been demonstrated on in vivo studies.
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2. C-reactive protein
C-reactive protein, a sensitive marker of inflammation and of the acute-phase
response, has been associated with cardiovascular disease in epidemiological and
experimental studies (Festa et al 2000, Kullo et al 2000, Pepys and Berger 2001). In 9
males CRP levels were inversely related to nitric oxide generation suggesting that
endothelial dysfunction plays a role in inflammation and CVD (Cleland et al 2000).
Levels of CRP in the upper third of the population distribution have been shown to have
twice the risk of a coronary event compared with individuals with baseline levels in the
bottom third (Pepys and Berger 2001). This relationship has also been shown for stroke
and peripheral vascular disease (Pepys and Berger 2001). CRP is likely involved with
the initiation or progression of atherosclerosis through its ability to stimulate tissue factor
production from macrophages, activate the complement system, to accumulate in
atherosclerotic lesions, to induce aggregation of LDL and VLDL and to be expressed by
monocytes (Festa et al 2000, Kullo et al 2000, Pepys and Berger 2001). CRP is strongly
associated with body fat and triacyglycerol. There is some indication that CRP may be
related to vWf or VCAM-1 (Cleland et al 2000). So far CRP has not been directly
studied in relation to diet but there is some indication that dietary fat may play a role in
cytokine production such as IL-6 thereby indirectly influencing CRP (Festa et al 2000).
However, well controlled experimental studies looking at the effect of MUFA on CRP
are not available and more research is needed in this area.
3. Interleukin-6
Genes coding for inflammatory cytokines such as interleukin-6 and adhesion
molecules have promoter-binding sites for NF-kB (Hennig et al 2000). An in vitro study
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using porcine pulmonary artery-derived endothelial cells cultured with 18 carbon fatty
acids varying in amount of unsaturation (18:0, 18:1, 18:2, and 18:3), showed that 18:1
had little effect on the activation of transcription factor NF-kB in comparison to 18:0 and
18:2 (Hennig et al 2000). It showed that when endothelial cells were treated with the
different fatty acids (90pmol/L) for 9 hours and tumor necrosis factor-a (TNF-a)
(500U/mL) for 3 more hours, that 18:1 produced the least increase in IL-6 production
although it was not significantly less than 18:0 or 18:3 (Hennig et al 2000). It therefore
appears that monounsaturated fat did not activate endothelial cells while n-6 fatty acids
seem to be the most effective activators (Hennig et al 2000).
In an in vitro study comparing several types of fatty acids it was found that DHA
and oleic acid to a lesser degree were able to inhibit the expression of adhesion
molecules. However, further experiments only focused on DHA since it resulted in the
most inhibition. DHA was found to decrease the production of IL-6 and although oleic
acid was not looked at it is possible that it would also have some effect as it did in
adhesion molecules (De Caterina and Libby 1996). It has been proposed that cytokines
such as IL-6 can stimulate the synthesis of acute-phase proteins (Festa et al 2000). From
these studies there is some indication that oleic acid is able to beneficially lower IL-6
levels, however, much more research is need in this area.
The studies that have looked at the effect of MUFA diets on hemostasis factors
have been able to show beneficial influences on several factors. In particular factor VII,
vWf and PAI-1 appear to be influenced by a MUFA rich diet. Preliminary in vitro
studies show promise for a MUFA rich diet being able to beneficially influence
inflammatory factors such as E-selectin and IL-6. Although there are only a few studies
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and the results are not consistent enough to be conclusive yet, there is enough evidence to
warrant further research with hemostatic and inflammatory factors and MUFA diets.
F. Research gap
a. Form of MUFA
All of the studies so far have looked at the effected of monounsaturated fatty acids
by using MUFA rich oils such as olive oil instead of a whole foods. This will be the first
time that the effect of a whole food (almonds) on hemostatic and inflammatory factors
will be investigated.
b. Methodology
Many of the previous studies that have looked at the effect of MUFA on
hemostatic and inflammatory factors have not used methodological rigor like the dose
response feeding study, conducted at Loma Linda University.
The conflicting results found in studies looking at diet and hemostasis and
inflammation may be due to differences in study designs, the type of subjects studied and
their baseline values of hemostatic and inflammatory factors, the total dietary
composition and the duration of studies (Vorster et al 1997). Besides methodological
issues, assay protocol and sample size, other confounding factors may be contributing to
the variability in results seen from previous studies.
It is clear that further studies are warranted in order to clearly establish the role if
any that MUFA has in influencing the different hemostatic and inflammatory factors.
Therefore, the “Dose Response Almond Feeding Study” provides an ideal data set in
which to study the effect of MUFA in the form of a whole food on hemostatic and
inflammatory factors.
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G. Almonds
It has been proposed that only modest increases in MUFA rich foods, in place of
SFA foods, are needed to achieve a desirable increase of MUFA in the diet in order to
lowering CVD risk (Kris-Etherton 1999). Almonds along with other MUFA rich foods
such as avocado, olives, sesame seeds, tahini and certain oils can be used to replace more
SFA rich foods in the diet (Kris-Etherton 1999).
1. Nutrient composition
Almonds are high in fat and the majority of fat comes from MUFA (Figs 7 and 8).
Nutrient Composition of Almonds (% by weight)

16.4
II Protein
M Carbohydrate

"U7

24.6

□ Fat

Figure 7. Nutrient composition of almonds (% by weight).

Almonds are rich in plant protein, fiber, vitamin E and other nutrients that along
with a high content of MUFA may have a beneficial impact on cardiovascular disease
risk (Kris-Etherton et al 1999).
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Fatty Acid Composition of Almonds (% of total fat by
weight)

□ SFA
H MUFA
□ PUFA

Figure 8. Fatty Acid Composition of Almonds (% of total fat by weight).

2. Lipoprotein effects
Nuts, such as almonds, that are high in monounsaturated fat have been shown to
protect against cardiovascular disease. It has been demonstrated that intake of nuts is
inversely related to cardiovascular disease risk and that nuts can result in the
postponement of disease development (Sabate 1999, Hu et al 1998, Fraser 1999, Kushi
et al 1996). One of the ways that almonds have been shown to lower the risk of CVD is
through their ability to impact lipids and lipoproteins. Cholesterol lowering diets that
incorporate nuts have been seen to have beneficial effects on total cholesterol and LDL
levels (Kris-Etherton et al 1999). These nut diets did not lower HDL or increase
triacyglycerol levels as low-fat, high carbohydrate diets tend to do (Kris-Etherton et al
1999). Diets containing nuts have been seen to lower lipid levels 25% more than would
be predicted by regression equations based on the fatty acid profile of the diet (KrisEtherton et al 1999). Almond supplemented diets have been shown to lower total
cholesterol and LDL levels (Hu et al 1998) and several human studies looking at almond
consumption and the effect on lipoproteins are reviewed in Table 3.
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Table 3. Human studies of almond consumption and impact on lipoproteins.
Study
Subjects
Study design
Length Diet
Results
Spiller
45 men and
Parallel
4 wk
• High-MUFA
High-MUFA
et al,
women
(almond)
(almond) vs.
1990
Hyper
• High-MUFA
baseline:
cholesterolemia
Itc
(olive oil)
• High-SFA
High-MUFA (olive
oil) vs. baseline:
(cheese,
Itc
butter)
Spiller
26 (13 men, 13
Consecutive
9 wk
High-MUFA
vs.
• Almond rich
et al
women).
supplemental
low SFA, low baseline:
1992
Hyper
study
Choi, high
Itc (pco.ooi)
cholesterolemia
fiber diet
Ildl
Spiller
et al
1998

45 (12 men, 33
women)
Free-living,
hyperlipidemic

Parallel

4 wk

• High-MUFA
(almond)
• High-MUFA
(olive oil)
• High-SFA
(cheese,
butter)

Abbey
et al
1994

16 men
Normolipidemic,
41 ± 9 years

Consecutive
supplemental
study

3 wk
each
diet

• Control diet
• High-MUFA
(almond)
• High-PUFA
(walnut)

Berry
et al,
1991

26 men

Randomized,
controlled,
crossover

12 wk
each
diet

Berry
et al,
1992

17 men

Randomized,
controlled,
crossover

12 wk
each
diet

• High-MUFA
(almonds,
olive oil,
avocado)
• High-PUFA
(walnuts,
safflower oil,
soybean oil)
• High-MUFA
(almonds,
olive oil,
avocados)
• Low-fat,
high-CHO
diet
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Between groups,
Almond-based diet.
I TC (p<0.001)
si LDL (p<0.001)
Within groups,
Almond-based diet:
si TC (p<0.05)
si LDL (p<0.001)
si TC:HDL (p<0.001)
High-MUFA vs.
control:
slTC
si LDL
High-PUFA vs.
control:
iTC
si LDL
High-MUFA vs.
baseline:
slTC
si LDL
High-PUFA vs.
baseline:
i TC
i LDL
High-MUFA vs.
baseline:

Itc
si LDL

It is clear that nuts are able to beneficially influence lipoprotein profiles, however,
their impact on hemostasis and inflammation is not as clearly understood and warrants
further investigation. Nuts have been clearly shown to lower the risk of CVD however
the amount of risk reduction is greater than can be explained by the impact on lipids and
lipoproteins. The objective of this study is to build on the data collected from the “Dose
Response Almond Feeding Study” by examining the effect of almond consumption on
hemostatic and inflammatory factors that can potentially explain the reduction in CVD
risk beyond what is explained by lowering of total and LDL cholesterol.
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CHAPTER THREE
III. OUTLINE OF THE RESEARCH
The Dose Response Almond feeding study was conducted in 1999 in the Nutrition
Department of Loma Linda University in with Joan Sabate, MD, DrPH, as the primary
investigator (Sabate et al 2001 submitted). The primary objective of the feeding study
was to determine the effect of almonds on blood lipids and lipoproteins in healthy adults.
During this study extra blood samples were stored for testing of secondary hypothesis
such as the current study that looked at the effect of almonds on hemostatic and
inflammatory factors.
A. Subjects
Subjects were included in the study if they were between the ages of 20 to 60
(40.9 ± 12.8) years, healthy with serum cholesterol in the range of 4.14 to 7.76 mmol/L
(160 to 300 mg/dL) and if their habitual diet prior to the study was close to the typical
American diet. Subjects were excluded if they had any previous history of hypertension.
arteriosclerosis or metabolic diseases, had any weight change six months prior to the
study, were taking medications known to affect serum lipids or consumed nuts frequently
(> 2 times/week).
B. Study Design
This study was a randomized, single-blind, crossover, controlled feeding trial
(Figure 9). At the beginning of the study there were 27 subjects, however 2 subjects
dropped out so that a total of 25 subjects completed the study. Subjects completed a 2
week run-in period during which they consumed a typical American diet (34 % energy
from fat). At the end of this period subjects were randomized to the three treatment diets
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Figure 9. Study Design of the Dose-Response Study.
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each of which was followed for four weeks. The control diet was a cholesterol-lowering
American Heart Association Step I diet (30 % energy from fat) and with no nuts. The
low (35 % energy from fat) and high (39 % energy from fat) almond diets were the same
as the Step I diet, with 10 % or 20 % of total calories of the Step I diet replaced with
almonds respectively. All meals were provided and prepared in the Nutrition department
metabolic kitchen. Breakfast and dinner were served on site while lunch and Saturday
meals were packed to go. This study was carried out with the highest degree of quality
control. A senior researcher was present at all meals and duplicate samples of the study
diets were chemically analyzed and compared with the composition of the diet planned
(Food Processor II, ESHA Research, Salem, OR). The compliance of subjects to diet and
study protocol were close to 100%. For more details on the study protocol please refer to
the original dose response almond feeding study (Sabate et al 2001 submitted).
C. Data collection and analysis
Fasting blood samples were collected during the run-in period and at the end of
each dietary period on alternate days (Wednesday and Friday). Blood draws were
42

performed at the nutrition department assessment laboratory, Loma Linda University.
The samples were centrifuged within 30 minutes of collection and the serum or plasma
aliquoted immediately and stored at -80°C until further analyzed. Samples were analyzed
by the CDC certified research laboratory, Department of pathology, University of
Vermont.
1. Rationale for selection
Several criteria were used in the selection of which assays to use. These included
the cost, availability of sample, blood collection method, sensitivity of the assay, validity
of the methodology to be used, and hemostatic and inflammatory factors that have
previously been shown to be influenced by diet.
2. Coagulation factor
Fibrinogen was measured in an automated clot-rate assay (Geffken et al 1994)
based upon the original method of Clauss (1957) using the ST4 instrument (Diagnostica
Stago) with standardization with the CAP reference material. Proficiency was checked
with the CAP Coagulation Proficiency Testing Program. Both frozen and lyophilized
controls were used. The minimum sample volume used for fibrinogen was 250 pL
citrated plasma. The analytical coefficient of variance (CV) for this assay was 1.65%.
The expected normal range is 163 to 363 mg/dL.
3. Fibrinolytic factor
Tissue plasminogen activator antigen (tPA ag) is a two-site immunoassay that
utilizes three different monoclonal antibodies (Holvoet et al 1985). This assay is
sensitive to both free tPA and tPA in complex with its inhibitors. Reagents for this assay
were generously provided by Drs. Collen and Declerck (Leuven, Belgium). The
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analytical coefficient of variance for this assay was 5.43% with an expected normal range
of 3.3 to 11.9 mg/L.
4. Inflammatory factors
E-selectin (Endothelial Leukocyte adhesion Molecule-1, ELAM-1, CD62E) was
measured using R&D Systems (Minneapolis, MN). This assay is very similar to the IL-6
assay with similar assay characteristics. The E-selectin assay utilizes two antibodies
directed against different epitopes on the E-selectin molecule in an ELISA technique for
quantitation. The usual sample volume is 100 pL of EDTA plasma. The coefficient of
variance for this assay was 4.0% with an expected normal range of 20.3 to 98.3 pg/L.
Interleukin-6, a major pro-inflammatory cytokine, was measured by ultra
sensitive ELISA (R&D Systems, Minneapolis, MN). The lower detection limit is less
than 0.10 ng/L with a detection range of 0.156-10.0 ng/L and the sample used was serum.
A monoclonal anti-IL-6 antibody was coated on the plastic support, and a polyclonal antiIL-6 antibody was used as the sandwich antibody. The amount of IL-6 bound was
determined by a color reaction. In the current modification of this commercial assay, the
minimum sample volume is 150 pL EDTA plasma. Using this method, a routine CV of
6.3% was determined. The expected normal range per the manufacturer is 0.24 to 12.5
ng/L (Harris et al 1999).
C-reactive protein (CRP) was measured by a colorimetric competitive ELISA
(Macy et al 1997). Biotinylated CRP competes with CRP in the sample for the coated
antibody. Detection was via the enzyme horseradish peroxidase conjugated in an avidinbiotin complex followed by the color reagent substrate, orthophenylene diamine.
Standardization was done using the WHO reference standard. The minimum sample
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volume was 50 jaL of EDTA plasma. The analytical coefficient of variance for this assay
was 5.14%. The expected normal range is 0.18 to 5.05 mg/L.
D. Statistical analysis
Statistical analysis was performed with the Statistical Analysis System, version
8.0 (SAS Institute Inc., Cary, NC). Duplicate measurements of the outcome variables
were averaged and the averages were used in further analysis. Changes in hemostatic
factors and markers of inflammation in response to dietary treatment were determined by
analysis of variance (ANOVA) using mixed linear models that included a random-effect
term for participants and fixed-effect term for diet and period. Tests for trend were
conducted by analysis of covariance (ANCOVA) by replacing the diet variables in the
above model with continuous variable representing the percent energy of the total energy
in the diet contributed by almonds. Results with a P value of 0.05 were considered
statistically significant. Results are reported as the mean ± SE. Fibrinogen, CRP and IL6 violated the assumption of homogeneity of variance. Therefore log transformed values
for these factors were used in statistical analysis.
Study participants completed diaries during the run-in and diet treatment periods.
Diary entries were reviewed and blood draw measurements were excluded from
statistical analysis for subjects with evidence of infection within a week prior to the blood
draw.
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Abstract
Background: Inflammation plays a major role in cardiovascular disease. Markers of
inflammation including C-reactive protein (CRP), E-selectin and interleukin-6 have been
proposed to be newer risk factors for cardiovascular disease.
Objective: The objective of this study was to determine the effect of almond
consumption on markers of inflammation and hemostatic factors in healthy adults.
Design: This was a randomized, crossover, controlled feeding study. After a 2-week
run-in period on a typical American diet (34% energy from fat), subjects were
randomized to the Step I diet, low almond diet and high almond diet (0%, 10% or 20%
isoenergetic replacement of Step I diet with almonds respectively), for four weeks each.
Serum fibrinogen, tPA, E-selectin, IL-6, CRP and lipoprotein(a) levels were analyzed at
the end of each dietary period.
Results: E-selectin was significantly lower on the almond diets and decreased as the
percentage of energy from almonds increased (P-trend <0.0001). CRP was statistically
significantly lower on the low (P=0.04) and high (P=0.03) almond diets in comparison to
the Step I diet. tPA was significantly lower on the Step I (P=0.01) and high almond
(P=0.004) diets compared with the low almond diet. Fibrinogen, IL-6 and lipoprotein(a)
were not significantly different between the three diets.
Conclusions: Consumption of almonds was able to lower levels of inflammatory
markers, E-selectin and CRP, which may be an indication of reduction in the
inflammatory process and thus impact CVD. However, other hemostatic and
inflammatory factors studied did not appear to be significantly influenced by the diets
enriched with almonds.
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Introduction
Inflammation is becoming increasingly acknowledged as having a major role in
the pathogenesis of cardiovascular disease (CVD) (1-6). Atherosclerosis may involve
subclinical thrombosis and inflammation that can result in the activation of the
hemostatic process (6). Acute exacerbations or activation of low-grade chronic
inflammation leads to vessel injury or disruption of an atherosclerotic plaque resulting in
exposure of prothrombotic factor within the plaque and activation of the hemostatic
process which can potentially precipitate CVD events (6-9). Low-grade chronic
inflammation may also contribute to cardiovascular events as a result of endothelial
dysfunction (3).
Markers of inflammation including C-reactive protein (CRP) and interleukin-6
(IL-6) and adhesion molecules such as E-selectin have been proposed as newer risk
factors for cardiovascular disease (1,5,10). Moderate elevations in C-reactive protein, a
sensitive marker of inflammation and of the acute-phase response, is associated with
cardiovascular disease in both healthy individuals (1,3,7,10,11) as well as those with
diagnosed vascular disease (3,7,11). Levels of CRP in the upper third of the population
distribution increase the risk of a coronary event twice as much compared to individuals
with baseline levels in the bottom third (7). Similarly CRP levels in the upper quartiles
had increased risk of myocardial infarction, stroke and peripheral vascular disease in the
Physicians’ Health Study and the Women’s Health Study (1,10,12). Models that include
CRP as well as lipid components are more effective in predicting coronary events than
when they are used alone (13).
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Interleukin-6, an inducible cytokine that can be produced at the site of injury,
promotes leukocyte adhesion and can stimulate hepatocytes to secrete acute phase
proteins such as CRP (10,14). There is some evidence that IL-6 is elevated in individuals
with chronic stable angina and that increased levels are associated with extent of disease
(15). E-selectin, an adhesion molecule, is stimulated by inflammatory cytokines and
along with other selectins has a critical role in atherogenesis contributing to the
regulation of the inflammatory process (4). Individuals with atherosclerosis and activated
endothelium have increased concentrations of adhesion molecules such as E-selectin
possibly due to an increase in oxidative stress (16).
As of yet there is no direct evidence showing that reductions of inflammatory
markers will result in reduced risk of cardiovascular disease and no therapies have been
developed to target markers of inflammation (1,13). However, there is some evidence to
suggest that CRP is involved with endothelial dysfunction and increases the expression of
adhesion molecules within plaques (1). Induction of adhesion molecules leading to
recruitment of monocytes and leukocytes is important in the progression of
atherosclerosis and the inflammatory response in plaques (2). Therefore CRP may prove
to be more than a marker of inflammation and may have some proinflammatory effects
on the endothelium (2). If this is the case therapies to lower CRP and other inflammatory
factors may indeed prove to be beneficial (1).
Recent evidence suggests that the benefits of aspirin for individuals with CVD
may in part be due to its anti-inflammatory actions (1,3,10,13). Statin drugs that inhibit
endogenous production of cholesterol have also been observed to lower CRP and thus
may be effective in reducing inflammation or cytokine production (3,7). This leads to the
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possibility that along with anti-inflammatory pharmacological agents modifying
inflammatory and hemostatic factors by dietary components may be beneficial in
reducing the risk of CVD.
There is some evidence that monounsaturated fat rich diets may influence
endothelial function (17). Oleic acid has been shown to inhibit the expression of
cytokine-inducible adhesion molecules including E-selectin in vitro thus reducing
endothelial activation (18). A few studies have looked at the effect of monounsaturated
fat rich diets on hemostasis factors and have found that they are able to lower levels of
plasminogen activator inhibitor-1 (PAI-1) (17,19,20), factor VII (19,21,22) and von
Willebrand factor (vWf) (17,23). However only one study has looked at E-selectin and it
was not significantly effected by diet (17). No feeding studies have yet been done
looking at CRP or IL-6. There is not conclusive evidence yet for an impact of
monounsaturated fat on markers of inflammation or hemostatic factors and none of the
previous studies have looked at monounsaturated fat from a whole food approach.
Therefore the purpose of this study is to examine the effect of monounsaturated
fat rich almonds, which are known to lower the risk of cardiovascular disease through
their impact on blood lipids and lipoproteins (24-28), on markers of inflammation in
healthy men and women.

50

Methods
Subjects
Subjects were included in the study if they were between the ages of 20 to 60
(mean age 40.9 ± 12.8) years, healthy with serum cholesterol in the range of 4.14 to 7.76
mmol/L (160 to 300 mg/dL) and if their habitual diet prior to the study was close to the
typical American diet. Subjects were excluded if they had any previous history of
hypertension, arteriosclerosis or metabolic diseases, had any weight change six months
prior to the study, were taking medications known to affect serum lipids or consumed
nuts frequently (> 2 times/week).
Study Design
This study was a randomized, single-blind, crossover, controlled feeding trial
(28). At the beginning of the study there were 27 subjects, however 2 subjects dropped
out so that a total of 25 subjects completed the study. Subjects completed a 2 week runin period during which they consumed a typical American diet (34 % energy from fat).
At the end of this period subjects were randomized to six different dietary treatment
sequences of three diets, each of which was followed for four weeks. The control diet
was a cholesterol-lowering American Heart Association (AHA) Step I diet (30 % energy
from fat) and no nuts. The low (35% energy from fat) and high (39% energy from fat)
almond diets were the same as the Step I diet, with 10 % or 20 % of total calories of the
Step I diet replaced with almonds respectively. All meals were provided and prepared in
the Nutrition department metabolic kitchen. Breakfast and dinner were served on site
while lunch and Saturday meals were packed to go. This study was carried out with the
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highest degree of quality control. The compliance of subjects to diet and study protocol
were close to 100% (28).
Data collection
Fasting blood samples were collected during the run-in period and at the end of
each dietary period on alternate days (Wednesday and Friday). Blood draws were
performed at the nutrition department assessment laboratory, Loma Linda University.
The samples were centrifuged within 30 minutes of collection and the serum or plasma
aliquotted immediately and stored at -80°C until further analysis. The samples were
analyzed in the CDC certified research laboratory, Department of pathology, University
of Vermont.
Fibrinogen was measured in an automated clot-rate assay (29) based upon the
original method of Clauss (30) using the ST4 instrument (Diagnostica Stago) with
standardization with the CAP reference material. Tissue plasminogen activator antigen
(tPA ag) is a two-site immunoassay that utilizes three different monoclonal antibodies
(31). This assay is sensitive to both free tPA and tPA in complex with its inhibitors. Eselectin (Endothelial Leukocyte adhesion Molecule-1, ELAM-1, CD62E) and interleukin6 were measured by ultra-sensitive ELISA (R&D Systems, Minneapolis, MN). Creactive protein was measured by a colorimetric competitive ELISA (32). Lipoprotein(a)
concentration was measured turbidimetrically (DiSarin Inc., Stillwater, MN).
Study participants completed diaries throughout the study. Since inflammatory
parameters like CRP are elevated with acute infection and trauma it is recommended that
testing done within 2-3 weeks of illness should be avoided (1). Diary entries were
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reviewed and blood draw measurements were excluded from statistical analysis for
subjects with evidence of infection within a week prior to the blood draw.
Statistical analysis
Statistical analysis was performed with the Statistical Analysis System, version
8.0 (SAS Institute Inc., Cary, NC). Duplicate measurements of the outcome variables
were averaged and the averages were used in further analysis. Changes in inflammatory
and hemostatic factors in response to dietary treatment were determined by analysis of
variance (ANOVA) using mixed linear models that included a random-effect term for
participants and fixed-effect term for diet and period. Tests for trend were conducted by
analysis of covariance by replacing the diet variables in the above model with continuous
variable representing the percent energy of the total energy in the diet contributed by
almonds. Results with a P value of 0.05 were considered statistically significant. Results
are reported as the least squares means ± SE. Fibrinogen, interleukin-6 and C-reactive
protein were found to violate the assumption of homogeneity of variance. Therefore log
transformed values were used for statistical analysis.
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Results
Table 4 shows the mean values for lipoprotien(a), fibrinogen, tPA antigen, Eselectin, IL-6 and CRP during each of the diet periods and Table 5 shows the mean
differences between the treatment diets for lipoprotein(a), hemostatic factors and
inflammatory factors.
Markers of inflammation tended to be lower on the almond diets. E-selectin
decreased significantly as the percentage of energy from almonds increased (P-trend
<0.0001). For each 1% increase in energy from almonds there was a decrease of 0.18
pg/L in E-selectin. E-selectin was significantly lower in the high almond diet compared
to both the Step I (P<0.0001) and low (P<0.0001) almond diets. However, there was no
statistically significant difference between the Step I diet and low almond diet for Eselectin. The dose response for CRP was statistically significant (P=0.03) with Creactive protein lower on the high almond diet (P=0.03) and low almond diet (P=0.04) in
comparison to the Step I diet. There was not a significant dose response for IL-6 and it
was not significantly different during any of the diet treatment periods.
Hemostatic factors, fibrinogen and tissue plasminogen activator antigen, did not
have a significant dose response trend. However, tPA ag was significantly lower during
the Step I (P=0.01) and high (P=0.004) almond diets compared to the low almond diet.
There was no significant dose response trend for lipoprotein(a) and it was not
significantly different between any of the diet treatment periods.
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Discussion
This study looked at the effect of monounsaturated fat rich almonds on markers of
inflammation and hemostatic factors. We found that increasing amounts of almonds
progressively lowered E-selectin and CRP in healthy men and women. However, other
inflammatory and hemostatic factors studied did not appear to be significantly influenced
by the almond diets.
In vitro studies have shown that monounsaturated fat inhibits the expression of Eselectin (18,33). A decrease in E-selectin could lower the inflammatory response related
to the recruitment of leukocytes and platelets and thus lower the risk of CVD. However,
previous feeding study by Perez-Jimenez et al (17) did not show a statistically significant
effect of monounsaturated fat on E-selectin. Although this study was similar to ours in
duration of feeding and percentage of energy obtained from fat there were a few
differences that may have contributed to the opposing outcomes. The baseline E-selectin
concentration reported by Perez-Jimenez et al (17) was almost half that observed in our
study. The effect of monounsaturated fat is probably seen only at higher concentrations
of E-selectin. Also subjects in the study by Perez-Jimenez et al (17) were men less than
30 years while our study had both men and women, from 20-60 years. The sources of
monounsaturated fat in the two studies were also different (almond vs. olive oil)
suggesting that other bioactive components in almonds besides fat may have influenced
plasma E-selectin levels in our study.
CRP is a sensitive marker of inflammation and acute-phase response and has been
associated with CVD in epidemiological and experimental studies (7,10,11). High levels
of CRP are strongly linked with coronary events, stroke and peripheral vascular disease
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(3,7). Neither IL-6 nor CRP has been previously examined by well-controlled
experimental feeding studies with monounsaturated fat but there is some indication that
dietary fat may play a role in cytokine production such as IL-6 thereby indirectly
influencing CRP (11). It is unclear yet what the pathophysiological role of CRP in
atherosclerosis is (10). CRP may be involved in atherogenesis by binding to LDL within
atherosclerotic plaques where it is proinflammatory, able to activate the complement
system and stimulate tissue factor production from macrophages (7,10). The exact
mechanism however needs to be further examined potentially through the development of
pharmacological agents that can inhibit CRP (7).
Although there was a significant decrease in CRP in our study when subjects were
fed almonds, based on risk estimates there was not a drop in quintile level and therefore
not a decrease in risk estimate (1). Subjects during all three diet periods were within the
third quintile (1.2 - 1.9 mg/L) with a moderate risk estimate for cardiovascular disease
(1). It is possible that almond diets for longer duration could lower CRP levels enough to
see a change in quintile level and may be more effective in those with already high
baseline levels.
Subjects with acute illness were only excluded 1 week prior to blood draws even
though it is recommended that testing within 2-3 weeks of illness should be avoided (1).
If longer treatment lengths had been used and if inflammatory markers had been a
primary outcome it would have been easier to exclude subjects for a longer duration and
to get blood draws after resolution of illness.
It would have been expected that along with a decrease in CRP levels there would
have been a similar decrease in IL-6 since it has been proposed that the ability of aspirin
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to lower CRP levels is probably as a result of lowered IL-6 (15). There is some
indication that dietary fat, particularly decosahexanoic acid and perhaps oleic acid, may
lower IL-6 in vitro (34) and indirectly influence CRP (11). An in vitro study has also
shown that oleic acid produces the least increase in IL-6 among all the saturated and
unsaturated fats (34). IL-6 tends to be lower in the morning and higher at night however
CRP does not appear to go through daily fluctuations (14). CRP levels tend to have long
term stability and do not fluctuate by time of day as do IL-6 levels (1). Therefore CRP
tends to be better able to predict cardiovascular disease in comparison with IL-6, which
may be in part due to a longer half life for CRP (14).
Several hemostatic factors were also examined and it was found that almond diets
do not seem to significantly influence any of these factors. Tissue plasminogen activator
antigen was significantly lower on the Step I and high almond diets in comparison to the
low almond diet. However, all levels of tPA ag were below the normal range and the
observed differences do not appear to be biologically relevant. Previous studies that have
looked at the effect of MUFA on fibrinogen have also shown no significant effect
(19,20,35). Increased concentrations of fibrinogen is one of the factors most strongly
associated with CVD risk (6,10) and there is some indication that fibrinogen is lowered
with an oleic acid diet (19). Thus we included the fibrinogen assay in our study. It is
possible that monounsaturated fat may have an impact in patients with abnormal baseline
levels. This needs to be explored in the future.
Lipoprotein(a) has been suggested as an independent predictor of CVD events
(10) and can hinder fibrinolysis by competing with plasminogen binding to fibrin,
inhibiting activation of plasminogen or increasing PAI-1 expression (10). Although there
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was no impact of almonds on lipoprotein(a), previous results in our lab have shown that
monounsaturated fat rich pecans (36) and polyunsaturated fat rich walnuts (37) lowered
lipoprotein(a) concentrations in normocholesterolemic and hypercholesterolemic subjects
respectively. It is unclear how much diet can influence lipoprotein(a).
Although our study did not show a measurable impact on hemostatic factors and
IL-6, future research in this area is still warranted. Our study was limited by a small
sample size since the primary outcome was blood lipids. Additionally, our subjects were
healthy and had normal values of all hemostatic and inflammatory factors. Perhaps the
effect of monounsaturated fat on markers of inflammation and hemostatic factors may be
more significant in subjects with abnormal baseline values. This needs to be explored in
the future. It is also likely that the dietary treatment duration of four weeks although
sufficient to see changes in blood lipids (38), may not be adequate to measure changes in
markers of inflammation and hemostatic factors.
Vitamin E supplementation has been associated with reduced risk of
cardiovascular disease (39,40). Some evidence has shown that vitamin E lowers markers
of inflammation (16,39) and fibrinolytic activity (41). However other studies have not
demonstrated an impact of vitamin E on adhesion molecules including E-selectin (39,40)
or lipoprotein(a) (39). Therefore in the current study analysis was also performed after
stratification for vitamin E supplementation (data not shown). There was a significant
dose response for E-selectin whether subjects took vitamin E or not which is consistent
with previous studies (39,40). However a significant dose response for CRP only
remained among those who used vitamin E supplements which may be an indication that
vitamin E contributed to the results. IL-6 and fibrinogen remained unaffected by diet
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whether subjects took vitamin E supplements or not. There was not a significant dose
response for tPA ag or lipoprotein(a) whether or not vitamin E supplements were taken
however among those who did not use supplements tPA ag was statistically significantly
lower on the high almond diet in comparison to the low almond diet and lipoprotein(a)
was significantly lower on the low almond diet in comparison to the Step I diet.
The results of this study indicate that monounsaturated fat rich almonds are able
to moderately impact markers of inflammation in healthy men and women. Such a
decrease may help to explain the ability of nuts such as almonds to lower the risk of
cardiovascular disease beyond their ability to impact blood lipids and lipoproteins
(reviewed in 25,42). Further research is warranted regarding the effect of nuts and
unsaturated fat on markers of inflammation. However, it is well established that
monounsaturated fat rich almonds and other nuts lower the risk of cardiovascular disease
by favorably modifying the blood lipid profile of individuals. Therefore it is still prudent
to incorporate almonds as part of a heart healthy diet as future studies explore their role in
modifying other CVD risk factors.
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Table 4. Period-adjusted serum E-selectin, interleukin-6, C-reactive protein,
fibrinogen, tissue plasminogen activator antigen and lipoprotein(a) at the end of
each dietary treatment. i
Low Almond
Variable

High Almond

Step I Diet2

P-trend
Diet2

Diet2

54.32 ±4.59

53.50 ±4.60

50.08 ±4.60

<0.0001

1.39 ±0.25

1.25 ±0.26

1.35 ±0.26

0.64

1.54 ±0.31

1.40 ±0.31

1.47 ±0.31

0.03

(mg/dL)

294.25 ± 11.79

295.38 ± 11.87

293.19 ± 11.88

0.89

(jitmol/L)

8.65 ±0.35

8.69 ±0.35

8.62 ±0.35

1.15 ± 0.18

1.29 ±0.18

1.12 ± 0.18

0.71

319.4 ±72.1

304.8 ±72.1

316.0 ±72.1

0.63

Inflammatory Factors:
E-selectin
(pg/L)
IL-6
(ng/L)
CRP
(mg/L)
Hemostatic Factors:
Fibrinogen

tPA ag
(pg/L)
Lipoprotein(a)
(mg/L)

Results derived from ANOVA models, which included diet and period effects.
" Least squares means ± SE.
Tissue plasminogen activator antigen (tPA ag); Interleukin-6 (IL-6); C-reactive protein
(CRP).
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Table 5. Mean differences in serum E-selectin, interleukin-6, C-reactive protein,
fibrinogen, tissue plasminogen activator antigen and lipoprotein(a)between dietary
treatments.1
Variable

Low Almond

High Almond

High Almond minus

minus Step I2

minus Step I2

Low Almond

-0.83 ± 0.69

-4.24 ± 0.693

-3.41 ±0.713

-0.14 ±0.12

-0.04 ±0.12

0.10 ± 0.12

-0.14 ± 0.074

-0.07 ± 0.074

0.07 ± 0.07

(mg/dL)

1.14 ±5.50

-1.05 ±5.51

-2.19 ±5.69

(pmol/L)

0.03 ±0.16

-0.03 ±0.16

-0.06 ±0.17

0.14 ± 0.065

-0.03 ± 0.06

-0.17 ± 0.065

-14.6 ±8.5

-3.4 ±8.5

11.2 ±8.8

2

Inflammatory Factors:
E-selectin
(|4g/L)
Interleukin-6
(ng/L)
C-reactive protein
(mg/L)
Hemostatic Factors:
Fibrinogen

tPA ag
(Fg/L)
Lipoprotein(a)
(mg/L)

Effect difference from ANOVA, which was controlled for period effect.
2 Difference of least squares means ± SE.
3 P <0.0001
4 P < 0.05
5 P <0.01
Tissue plasminogen activator antigen (tPA ag).
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CHAPTER FIVE
V. SUMMARY AND CONCLUSIONS
A. Summary and conclusions
This study looked at the effect of monounsaturated fat rich almonds on hemostatic
and inflammatory factors. We found that increasing amounts of almonds progressively
lowered E-selectin and CRP concentrations in healthy men and women. E-selectin levels
on the high almond diet were significantly lower than on the low almond and Step I diets.
CRP levels were also significantly lower on the low and high almond diets in comparison
with the Step I diet although there was not a change in quintile level and thus not a
decrease in CVD risk estimate. However it is possible that almond diets for longer
duration could lower CRP levels enough to see a change in quintile level and may be
more effective in those with already high baseline levels. Therefore it appears that
monounsaturated fat rich almonds are able to moderately impact markers of inflammation
in healthy men and women. Such a decrease may help to explain the ability of nuts such
as almonds to lower the risk of cardiovascular disease beyond their ability to impact
blood lipids and lipoproteins.
Several hemostatic factors were also examined and it was found that almond diets
do not seem to significantly influence any of these factors. Tissue plasminogen activator
antigen was significantly lower on the Step I and high almond diets in comparison to the
low almond diet. However, all levels of tPA ag were below the normal range and the
observed differences do not appear to be biologically significant.
The primary outcome measure for the almond feeding study was blood lipids and
lipoproteins. Therefore sample size (n=24) and sample collections were based on these
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outcome measures instead of on hemostatic and inflammatory factors. A sample size of
36 would have been required at alpha = 0.05 and a power of 0.8 if the primary outcome
objective was markers of inflammation and hemostatic factors using PAI-1 as the
outcome variable. It is also likely that the dietary treatment duration of four weeks
although sufficient to see changes in blood lipids (Kris-Etherton and Dietschy 1997), may
not be adequate to measure changes in markers of inflammation and hemostatic factors.
Subjects with acute illness were only excluded 1 week prior to blood draws even
though it is recommended that testing within 2-3 weeks of illness should be avoided
(Ridker 2001). If longer treatment lengths had been used and if inflammatory markers
had been a primary outcome it would have been easier to exclude subjects for a longer
duration and to get blood draws after resolution of illness.
Samples were stored for over a year and it is assumed that the activity and
concentration of hemostatic and inflammatory factors persists when stored long-term at
or below -70 ° C (Pearson et al 1997). It is not well understood if freezing and storage
may introduce artifacts or variability (Pearson et al 1997). Feeding studies have the
potential for non-compliance with dietary treatments. However, non-compliance was
minimized through the incorporation of a run-in period and the presence of a senior
researcher at each of the meals.
Exclusion/inclusion criteria were also based on the primary outcome measures,
which were blood lipids and lipoproteins. Therefore subjects were not excluded for some
criteria that can potentially influence markers of inflammation and hemostatic factors.
Smoking, age, body size, diabetes, LDL-C, Lp(a), leukocyte count and menopause (Kullo
et al 2000) influence fibrinogen. PAI-1 has been associated with triacylglycerol
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concentrations and linked with the insulin resistance syndrome or syndrome X (Tracy
1997, Pearson et al 1997). tPA may be influenced by physical activity (Pearson et al
1997). CRP is associated with smoking, hypertension, hypercholesterolemia, obesity and
diabetes (Kullo et al 2000). Several markers of inflammation and hemostatic factors such
as fibrinogen, Lp(a) are acute phase reactants and therefore elevated after surgery.
infection, trauma or myocardial infarction (Pearson et al 1997).
B. Future directions
Further research is needed to understand the exact role, if any, of
monounsaturated fat rich foods such as almonds on hemostatic and inflammatory factors
before drawing conclusions for public health. If almonds are able to influence
inflammation it would be beneficial for future studies to explore potential mechanisms by
which almonds are able to impact inflammation, either through fat components or other
bioactive components in almonds. It would be beneficial to clarify the impact of vitamin
E on markers of inflammation and hemostatic factors. Since the pathophysiological role
of CRP in atherosclerosis is unclear it would be beneficial for future research to examine
mechanisms for how CRP is involved in atherogenesis.
Future studies should focus on hemostatic and inflammatory factors as primary
research outcome variables. Methods should include adequate sample size and treatment
duration to be able to detect significant changes in hemostatic and inflammatory factors.
Sample collection should be specific for inflammatory and hemostatic factors and long
term storage even at appropriate temperatures should be kept to a minimum. It would
also be meaningful to look at the effect of monounsaturated fat on patients with
hemostatic and inflammatory factors outside the normal values.
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The research on almonds and markers of inflammation and hemostasis needs to be
clarified and further research is warranted regarding the effect of nuts and unsaturated fat
on markers of inflammation. However, it is well established that monounsaturated fat
rich almonds and other nuts lower the risk of cardiovascular disease by favorably
modifying the blood lipid profile of individuals. Therefore it is still prudent to
incorporate almonds as part of a heart healthy diet as future studies explore their role in
modifying other CVD risk factors.
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